Eye camera could be used as a retina implant

Article

A camera the size and shape of a human eye could have a diverse range of applications, including being used as a retinal implant and in brain monitoring and cardiac stimulation, according to research published in Nature.

A camera the size and shape of a human eye could have a diverse range of applications, including being used as a retinal implant and in brain monitoring and cardiac stimulation, according to research published in Nature.

John Rogers of the Beckman Institute at the University of Illinois at Urbana-Champaign, US and colleagues constructed the hemispherical camera from a stretchable sheet of “optoelectronics”, consisting of a mesh of silicon pixels connected by flexible plastic ribbon cables to create photodetector arrays. The mesh is transferred to a hemispherical rubber membrane, and then onto glass, where a hemispherical cap with lens is added.

Although the camera provides a wider field of view and fewer aberrations than flat cameras, currently it has only a few hundred pixels, limiting the sharpness of the images captured. The research team is currently collaborating with the University of Pennsylvania in the US to expand the abilities of the camera.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.